Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
natalizumab and interferon beta-1a
- Development stage
- Unknown
- Lead developer
- Biogen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous, Intramuscular
01
Overview
This is a combination of two disease-modifying therapies for multiple sclerosis. Natalizumab (TYSABRI) is an integrin receptor antagonist administered as an intravenous infusion every four weeks. Interferon beta-1a (AVONEX) is administered as an intramuscular injection once weekly. Clinical trials showed that the combination provided a 24% lower risk of symptom worsening compared to AVONEX alone.
- Brand names
- TYSABRIAVONEX
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)ITGA4 (Integrin alpha-4)
Beyond the preview
Go deeper on natalizumab and interferon beta-1a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on natalizumab and interferon beta-1a.